Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg
Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan metolazone 5 mg
tablets to Celltech Zaroxolyn® 5 mg tablets following a single, oral 10 mg (2 x 5 mg) dose
administration under fasting conditions.